Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

$SHC
Misc Health and Biotechnology Services
Health Care
Get the next $SHC alert in real time by email

CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025.

Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders.

Mr. Petrella has decades of public company executive leadership and board experience. "Since joining our Board, Vince's experience, insight and engagement have been invaluable as chairperson of our Audit Committee. We are delighted to benefit from his continued knowledge and guidance as our Lead Independent Director," said Michael B. Petras, Jr., Sotera Health Chairman and Chief Executive Officer.

"It is a great privilege to engage with Sotera Health leadership and the Board, and I'm excited by this opportunity to lead in an expanded way," Mr. Petrella said. "I appreciate the confidence of the Board and look forward to continuing to support Sotera Health and drive shareholder value."

About Vincent K. Petrella

Mr. Petrella served as the Executive Vice President, Chief Financial Officer and Treasurer at Lincoln Electric Holdings, Inc., a welding, cutting and brazing products manufacturer from 2004 until April 2020. He is currently a board member of Applied Industrial Technologies, Inc. and the Gorman-Rupp Company.

About Sotera Health

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company's website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health.

INVESTOR RELATIONS CONTACT

Jason Peterson

Vice President, Investor Relations & Treasurer

IR@soterahealth.com

MEDIA CONTACT

Kristin Gibbs

Chief Marketing Officer

kgibbs@soterahealth.com

Source: Sotera Health Company



Primary Logo

Get the next $SHC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SHC

DatePrice TargetRatingAnalyst
12/6/2024$14.00Neutral
Goldman
5/21/2024$13.00Neutral
Piper Sandler
4/3/2024$18.00 → $16.00Neutral → Buy
Citigroup
3/25/2024$15.00 → $15.50Hold → Buy
Jefferies
2/6/2024Sector Weight
KeyBanc Capital Markets
6/26/2023$24.00Sector Weight → Overweight
KeyBanc Capital Markets
1/23/2023$6.00 → $18.00Underweight → Neutral
JP Morgan
1/11/2023$6.00 → $22.00Underweight → Overweight
Barclays
More analyst ratings

$SHC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Nelson Labs Launches Innovative Rapid Sterility Testing to Significantly Expedite Product Sterility Results

    SALT LAKE CITY, March 04, 2025 (GLOBE NEWSWIRE) -- Nelson Labs, a Sotera Health company and a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries, now performs product-sterility testing through rapid microbiological methods (RMMs) at three laboratory sites located in the United States and Europe. Nelson Labs' testing solution is unique in that it supports a broad range of both medical devices and pharmaceutical products. This innovative approach broadens the scope of Rapid Sterility Testing—a field that has primarily focused on products with biological components or short shelf life—by providing a vers

    $SHC
    Misc Health and Biotechnology Services
    Health Care
  • Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook

    2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted share, compared to 20232024 Adjusted EBITDA(1) increased 3.9% to $549 million, compared to 2023; or 4.6% on a constant currency basis2024 Adjusted EPS(1) of $0.70, a decrease of $0.02 per diluted share, compared to 2023Full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization so

    $SHC
    Misc Health and Biotechnology Services
    Health Care
  • Sotera Health Announces Fourth-Quarter and Full-Year 2024 Earnings Release Date

    CLEVELAND, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2024 before the market opens on Thursday, February 27, 2025. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from

    $SHC
    Misc Health and Biotechnology Services
    Health Care

$SHC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SHC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SHC
SEC Filings

See more

$SHC
Leadership Updates

Live Leadership Updates

See more
  • Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

    CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

    $SHC
    Misc Health and Biotechnology Services
    Health Care
  • Sotera Health Appoints Christopher Simon to the Board of Directors

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services
  • Sotera Health Appoints Karen Flynn to Board of Directors

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

    $CTLT
    $QTRX
    $SHC
    $WST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$SHC
Financials

Live finance-specific insights

See more
  • Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook

    2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted share, compared to 20232024 Adjusted EBITDA(1) increased 3.9% to $549 million, compared to 2023; or 4.6% on a constant currency basis2024 Adjusted EPS(1) of $0.70, a decrease of $0.02 per diluted share, compared to 2023Full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization so

    $SHC
    Misc Health and Biotechnology Services
    Health Care
  • Sotera Health Announces Fourth-Quarter and Full-Year 2024 Earnings Release Date

    CLEVELAND, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2024 before the market opens on Thursday, February 27, 2025. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results. To participate in the live call, please dial 1-844-481-2916 if dialing-in from the United States, or 1-412-317-0709 if dialing-in from

    $SHC
    Misc Health and Biotechnology Services
    Health Care
  • Sotera Health Reports Third-Quarter and Year-to-Date 2024 Results

    Q3 2024 net revenues of $285 million increased 8.5%, compared to Q3 2023Q3 2024 net income of $17 million or $0.06 per diluted share, compared to net loss of $14 million or $0.05 per diluted share in Q3 2023 Q3 2024 Adjusted EBITDA(1) of $146 million increased 9.0%, compared to Q3 2023Q3 2024 Adjusted EPS(1) of $0.17 increased $0.01 per diluted share, compared to Q3 2023Reaffirming 2024 Net Revenue and Adjusted EBITDA outlook ranges CLEVELAND, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry,

    $SHC
    Misc Health and Biotechnology Services
    Health Care

$SHC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more